DOCSLIB.ORG

August 2021 Vectorborne Infectious Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
August 2021 Vectorborne Infectious Diseases 1913.),Culebra Jonas( OilLie Cut, on(1880−1940) canvas, Panama 60 Canal in The x 50 Conquerors in/ 152.4 cm x 127 cm. InfectiousDiseases Vectorborne Image copyright © The Metropolitan Museum of Art, New York, NY, United States. Image source: Art Resource, New York, NY, United States. August 2021 ® Peer-Reviewed Journal Tracking and Analyzing Disease Trends Pages 2008–2250 ® EDITOR-IN-CHIEF D. Peter Drotman ASSOCIATE EDITORS EDITORIAL BOARD Charles Ben Beard, Fort Collins, Colorado, USA Barry J. Beaty, Fort Collins, Colorado, USA Ermias Belay, Atlanta, Georgia, USA Martin J. Blaser, New York, New York, USA David M. Bell, Atlanta, Georgia, USA Andrea Boggild, Toronto, Ontario, Canada Sharon Bloom, Atlanta, Georgia, USA Christopher Braden, Atlanta, Georgia, USA Richard Bradbury, Melbourne, Australia Arturo Casadevall, New York, New York, USA Corrie Brown, Athens, Georgia, USA Benjamin J. Cowling, Hong Kong, China Kenneth G. Castro, Atlanta, Georgia, USA Michel Drancourt, Marseille, France Christian Drosten, Charité Berlin, Germany Paul V. Effler, Perth, Australia Isaac Chun-Hai Fung, Statesboro, Georgia, USA Anthony Fiore, Atlanta, Georgia, USA Kathleen Gensheimer, College Park, Maryland, USA David O. Freedman, Birmingham, Alabama, USA Rachel Gorwitz, Atlanta, Georgia, USA Peter Gerner-Smidt, Atlanta, Georgia, USA Duane J. Gubler, Singapore Stephen Hadler, Atlanta, Georgia, USA Scott Halstead, Arlington, Virginia, USA Matthew J. Kuehnert, Edison, New Jersey, USA Nina Marano, Atlanta, Georgia, USA David L. Heymann, London, UK Martin I. Meltzer, Atlanta, Georgia, USA Keith Klugman, Seattle, Washington, USA David Morens, Bethesda, Maryland, USA S.K. Lam, Kuala Lumpur, Malaysia J. Glenn Morris, Jr., Gainesville, Florida, USA Shawn Lockhart, Atlanta, Georgia, USA Patrice Nordmann, Fribourg, Switzerland John S. Mackenzie, Perth, Australia Johann D.D. Pitout, Calgary, Alberta, Canada John E. McGowan, Jr., Atlanta, Georgia, USA Ann Powers, Fort Collins, Colorado, USA Jennifer H. McQuiston, Atlanta, Georgia, USA Didier Raoult, Marseille, France Pierre E. Rollin, Atlanta, Georgia, USA Tom Marrie, Halifax, Nova Scotia, Canada Frederic E. Shaw, Atlanta, Georgia, USA Nkuchia M. M’ikanatha, Harrisburg, Pennsylvania, USA David H. Walker, Galveston, Texas, USA Frederick A. Murphy, Bethesda, Maryland, USA J. Todd Weber, Atlanta, Georgia, USA Barbara E. Murray, Houston, Texas, USA J. Scott Weese, Guelph, Ontario, Canada Stephen M. Ostroff, Silver Spring, Maryland, USA Associate Editor Emeritus W. Clyde Partin, Jr., Atlanta, Georgia, USA Charles H. Calisher, Fort Collins, Colorado, USA Mario Raviglione, Milan, Italy and Geneva, Switzerland Managing Editor David Relman, Palo Alto, California, USA Byron Breedlove, Atlanta, Georgia, USA Connie Schmaljohn, Frederick, Maryland, USA Copy Editors Deanna Altomara, Dana Dolan, Terie Grant, Tom Schwan, Hamilton, Montana, USA Thomas Gryczan, Amy Guinn, Shannon O’Connor, Rosemary Soave, New York, New York, USA Tony Pearson-Clarke, Jill Russell, Jude Rutledge, Robert Swanepoel, Pretoria, South Africa P. Lynne Stockton, Deborah Wenger David E. Swayne, Athens, Georgia, USA Production Thomas Eheman, William Hale, Barbara Segal, Kathrine R. Tan, Atlanta, Georgia, USA Reginald Tucker Phillip Tarr, St. Louis, Missouri, USA Journal Administrator Susan Richardson Neil M. Vora, New York, New York, USA Duc Vugia, Richmond, California, USA Editorial Assistants J. McLean Boggess, Kaylyssa Quinn Mary Edythe Wilson, Iowa City, Iowa, USA Communications/Social Media Heidi Floyd, Sarah Logan Gregory Emerging Infectious Diseases is published monthly by the Centers for Disease Control Founding Editor and Prevention, 1600 Clifton Rd NE, Mailstop H16-2, Atlanta, GA 30329-4027, USA. Joseph E. McDade, Rome, Georgia, USA Telephone 404-639-1960; email, [email protected] The conclusions, findings, and opinions expressed by authors All material published in Emerging Infectious Diseases is in the contributing to this journal do not necessarily reflect the official public domain and may be used and reprinted without special position of the U.S. Department of Health and Human Services, permission; proper citation, however, is required. the Public Health Service, the Centers for Disease Control and Use of trade names is for identification only and does not imply Prevention, or the authors’ affiliated institutions. Use of trade names endorsement by the Public Health Service or by the U.S. Department is for identification only and does not imply endorsement by any of of Health and Human Services. the groups named above. EMERGING INFECTIOUS DISEASES is a registered service mark of the U.S. Department of Health & Human Services (HHS). Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No. 8 August, 2021 Vectorborne Infectious Diseases August 2021 Synopses Mycobacterium microti Infections in Free-Ranging Red Deer (Cervus elaphus) G. Ghielmetti et al. 2025 Plague Transmission from Corpses and Carcasses S. Jullien et al. 2033 Four Human Cases of Eastern Equine Encephalitis in Connecticut, USA, during a Larger Regional Outbreak, 2019 Increased incidence of equine and human disease was observed after primary and bridge mosquito vectors more than doubled normal levels earlier in the season than usual. S.C. Brown et al. 2042 Research Transmission Dynamics of Severe Acute Respiratory Syndrome-Coronavirus-2 in High-Density Settings, Minnesota, USA, March–June 2020 N.B . Lehnertz et al. 2052 Intense and Mild First Epidemic Wave of Coronavirus Disease, The Gambia B. Abatan et al. 2064 On the Cover Peridomestic Mammal Susceptibility to Severe Acute Jonas Lie (1880−1940) The Conquerors (Culebra Cut, Respiratory Syndrome Coronavirus 2 Infection Panama Canal), 1913. Oil on canvas, 60 in x 50 in/ 152.4 cm x 127 cm. Image copyright © The Metropolitan Museum of Art, New A.M. Bosco-Lauth et al. 2073 York, NY, United States. Image source: Art Resource, New York, NY, United States. Effects of Patient Characteristics on Diagnostic Performance of Self-Collected Samples for About the Cover p. 2244 SARS-CoV-2 Testing S.E. Smith-Jeffcoat et al. 2081 Perspective Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa Fungemia and other Fungal Infections V. Williams et al. 2009 Associated with Use of Saccharomyces boulardii Probiotic Supplements Comparison of Lyme Disease in the United States Use of these supplements should be considered carefully for patients and Europe whose gastrointestinal tract integrity might be compromised. A.R. Marques et al. 2017 J. Rannikko et al. 2090 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No. 8, August 2021 August 2021 Dispatches Zoonotic Soil-Transmitted Helminths in Free-Roaming Dogs, Kiribati P.A. Zendejas-Heredia et al. 2163 SARS-CoV-2 Prevalence among Outpatients during Community Transmission, Zambia, July 2020 2020 J.Z. Hines et al. 2166 Estimates of Toxoplasmosis Incidence Based on Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Health Care Claims Data, Germany, 2011–2016 Vaccination in Long-Term Care Facility, Germany, A. Krings et al. 2097 February–March 2021 P. Tober-Lau et al. 2169 Modeling Immune Evasion and Vaccine Limitations by Targeted Nasopharyngeal Bordetella pertussis Delayed Antibody and T-Cell Response to Inoculation in Mice BNT162b2 Vaccination in the Elderly, Germany I.H. Soumana et al. 2107 T. Schwarz et al. 2174 Spotted Fever Group Rickettsioses in Israel, Autochthonous Cases of Tick-borne Encephalitis, 2010–2019 Belgium, 2020 R. Cohen et al. 2117 A. Stoefs et al. 2179 Spatial, Ecologic, and Clinical Epidemiology Epidemiology of COVID-19 in Prisons, England, 2020 of Community-Onset, Ceftriaxone-Resistant W.M. Rice et al. 2183 Enterobacteriaceae, Cook County, Illinois, USA V. Sardá et al. 2127 Natural Human Infections with Plasmodium cynomolgi, P. inui and 4 other Simian Malaria Social Distancing, Mask Use, and Transmission Parasites, Malaysia of Severe Acute Respiratory Syndrome N.J. Yap et al. 2187 Coronavirus 2, Brazil, April–June 2020 M.R. Gonçalves et al. 2135 Weekly SARS-CoV-2 Sentinel Surveillance in Primary Schools, Kindergartens, and Nurseries, Costs and Outcomes of Integrated Human African Germany, June‒November 2020 Trypanosomiasis Surveillance System Using Rapid M. Hoch et al. 2192 Diagnostic Tests, Democratic Republic of the Congo R. Snijders et al. 2144 Genomic Detection of Schmallenberg Virus, Israel A. Behar et al. 2197 Epidemiology and Spatial Emergence of Anaplasmosis, New York, USA, 2010‒2018 Parasitic Disease Surveillance, Mississippi, USA A. Russell et al. 2154 R.S. Bradbury et al. 2201 2027 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No. 8, August 2021 2164 August 2021 Letters Post-13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children C. Levy et al. 2240 Estimate of Burden and Direct Healthcare Cost of Screening for Q Fever in Patients Undergoing Infectious Waterborne Disease in the United States Transcatheter Aortic Valve Implantation, Israel, S. DeFlorio-Barker et al. 2241 June 2018–May 2020 N. Ghanem-Zoubi et al. 2205 Books and Media African Horse Sickness Virus Serotype 1 on Horse Farm, Thailand, 2020 The Yellow Flag: Quarantine and the British N. Bunpapong et al. 2208 Mediterranean World, 1780–1860 R. Wurtz 2243 Replication in Human Intestinal Enteroids of Infectious Norovirus from Vomit Samples M. Hagbom et al. 2212 About the Cover Endogenous Endophthalmitis Caused by ST66-K2 Special Wonders of the Canal Hypervirulent Klebsiella pneumoniae, United States B. Breedlove 2244 E. Kamau et al. 2215 Etymologia
Load more

Recommended publications
  • Official Nh Dhhs Health Alert
    THIS IS AN OFFICIAL NH DHHS HEALTH ALERT Distributed by the NH Health Alert Network [email protected] May 18, 2018, 1300 EDT (1:00 PM EDT) NH-HAN 20180518 Tickborne Diseases in New Hampshire Key Points and Recommendations: 1. Blacklegged ticks transmit at least five different infections in New Hampshire (NH): Lyme disease, Anaplasma, Babesia, Powassan virus, and Borrelia miyamotoi. 2. NH has one of the highest rates of Lyme disease in the nation, and 50-60% of blacklegged ticks sampled from across NH have been found to be infected with Borrelia burgdorferi, the bacterium that causes Lyme disease. 3. NH has experienced a significant increase in human cases of anaplasmosis, with cases more than doubling from 2016 to 2017. The reason for the increase is unknown at this time. 4. The number of new cases of babesiosis also increased in 2017; because Babesia can be transmitted through blood transfusions in addition to tick bites, providers should ask patients with suspected babesiosis whether they have donated blood or received a blood transfusion. 5. Powassan is a newer tickborne disease which has been identified in three NH residents during past seasons in 2013, 2016 and 2017. While uncommon, Powassan can cause a debilitating neurological illness, so providers should maintain an index of suspicion for patients presenting with an unexplained meningoencephalitis. 6. Borrelia miyamotoi infection usually presents with a nonspecific febrile illness similar to other tickborne diseases like anaplasmosis, and has recently been identified in one NH resident. Tests for Lyme disease do not reliably detect Borrelia miyamotoi, so providers should consider specific testing for Borrelia miyamotoi (see Attachment 1) and other pathogens if testing for Lyme disease is negative but a tickborne disease is still suspected.
    [Show full text]
  • Covid-19: Reflecting on Experience and Anticipating the Next Steps
    Perspectives on COVID-19 13 COVID-19: REFLECTING ON EXPERIENCE AND ANTICIPATING THE NEXT STEPS A perspective from the WHO Regional Office for Europe By: Hans Henri P. Kluge, Dorit Nitzan and Natasha Azzopardi-Muscat Cite this as: Eurohealth 2020; 26(2). Hans Henri P. Kluge is Regional Director, Dorit Nitzan is Regional Emergency Director, Natasha Azzopardi Muscat is Director, Country Health Policies and Systems; World Health Organization (WHO) Regional Office for Europe, Copenhagen, Denmark. Nine months into the COVID-19 Health Systems Response Monitor which forced our health systems to adjust with pandemic, devastation and disruption was established at the request of the unprecedented speed. Central to these across much of the European Region WHO Regional Office for Europe in the efforts was our health workforce. We continues unabated. A sharp and sustained early days of the pandemic, has provided must first and foremost prioritise their increase in cases is forcing governments invaluable experience in a timely fashion. well-being including providing adequate to navigate complex response tactics as This has allowed policy considerations mental, physical and financial support, they seek to control disease transmission, and technical /operational guidance to be and continuous training and education. If while also seeking to avoid the negative developed in a rapid response manner. we do not care for them, we will have no consequences associated with lockdowns. health system to depend on. In our view, there are three key lessons At this juncture we are dealing both that should form the foundation of the Health care systems need to operate a with the aftermath of the initial stages evolving COVID-19 response and long- dual track service delivery.
    [Show full text]
  • The Definition and Measurement of Dangerous Research
    Center for International and Security Studies at Maryland The Definition and Measurement of Dangerous Research Alex Greninger July 2004 CISSM School of Public Policy This paper was prepared as part of the Advanced Methods of Cooperative Security Program at 4113 Van Munching Hall the Center for International and Secuirty Studies at Maryland, with generous support from the University of Maryland John D. and Catherine T. MacArthur Foundation. College Park, MD 20742 Tel: 301-405-7601 [email protected] Outline I. Introduction to the Biological Research Security System Model A. The 3-D Definition of Danger 1. Define Transmissibility 2. Define Infectivity 3. Define Lethality B. Defining the Project At Hand C. Where Do Candidate Pathogens Fit into the Danger Terrian? II. Influenza A. Parameter Background 1. Transmissibility 2. Lethality 3. Infectivity B. Highlighting Problematic Research That Has Been Done 1. General Pathogenesis 2. Determinants of 1918 Influenza Pathogenesis 3. Determinants of H5N1 Virus Pathogenesis C. Highlighting Problematic Research That Could Be Done D. Difficulties in Creating an Oversight System for Influenza Research E. Recommendations for Influenza Research III. Pneumonic Plague A. Parameter Background 1. Transmissibility 2. Infectivity 3. Lethality 4. Conclusions B. Highlighting Problematic Research That Has Been Done 1. Increasing Presentation or Activity of Virulence Factors 2. Therapy and Prophylaxis Resistance C. Highlighting Problematic Research That Could Be Done D. Conclusions IV. Conclusions A. Recommendations 1. Include Countermeasures 2. Build the Science of Transmissibility 3. Recognize the Threat Presented By Host Susceptibility and Immunology 4. Keep Weaponization Information Under Control 5. Is Infectivity Useful? B. Long-Term Dilemmas 1.
    [Show full text]
  • June 11, 2021 the Honorable Xavier Becerra Secretary Department of Health and Human Services 200 Independence Ave S.W. Washingto
    June 11, 2021 The Honorable Xavier Becerra Secretary Department of Health and Human Services 200 Independence Ave S.W. Washington, D.C. 20201 The Honorable Francis Collins, M.D., Ph.D. Director National Institutes of Health 9000 Rockville Pike Rockville, MD 20892 Dear Secretary Becerra and Director Collins, Pursuant to 5 U.S.C. § 2954 we, as members of the United States Senate Committee on Homeland Security and Governmental Affairs, write to request documents regarding the National Institutes of Health’s (NIH) handling of the COVID-19 pandemic. The recent release of approximately 4,000 pages of NIH email communications and other documents from early 2020 has raised serious questions about NIH’s handling of COVID-19. Between June 1and June 4, 2021, the news media and public interest groups released approximately 4,000 pages of NIH emails and other documents these organizations received pursuant to Freedom of Information Act requests.1 These documents, though heavily redacted, have shed new light on NIH’s awareness of the virus’ origins in the early stages of the COVID- 19 pandemic. In a January 9, 2020 email, Dr. David Morens, Senior Scientific Advisor to Dr. Fauci, emailed Dr. Peter Daszak, President of EcoHealth Alliance, asking for “any inside info on this new coronavirus that isn’t yet in the public domain[.]”2 In a January 27, 2020 reply, Dr. Daszak emailed Dr. Morens, with the subject line: “Wuhan novel coronavirus – NIAID’s role in bat-origin Covs” and stated: 1 See Damian Paletta and Yasmeen Abutaleb, Anthony Fauci’s pandemic emails:
    [Show full text]
  • RHODE ISLAND M Edical J Ournal
    RHODE ISLAND M EDICAL J ournaL DANIEL HALPREN-RUDER, MD, PhD JOHN R. LONKS, MD ANTHONY E. MEGA, MD FRED J. SCHIFFMAN, MD JON A. MUKAND, MD, PhD LYNN E. TAYLOR, MD MARIA A. MILENO, MD JENNIE E. JOHNSON, MD BRETT D. OWENS, MD RAMIN R. TABADDOR, MD JIE TANG, MD, MPH, MSc WEN-CHIH WU, MD, MPH RIMJ GUEST EDITORS of 2020 See story, page 21 DECEMBER 2020 VOLUME 103 • NUMBER 10 ISSN 2327-2228 URGENT RESOURCES FOR URGENT TIMES. In a pandemic, speed and access to information and You can access Coverys’ industry-leading Risk resources are vital. Management & Patient Safety services, videos, and staff training at coverys.com. Knowledge saves time, and you need all the time you can get to save lives. Introducing the COVID-19 Resource Center. All in one place, for our policyholders as well as for all Right here, right now, for you. healthcare providers. On our website, you’ll find the latest information and Thank you. For all that you are doing. You are our heroes, resources for important topics like: and we are here if you need us. • Telemedicine: including best practices and plain language consent forms • Links to infectious disease prevention guidance • Education and resources for healthcare providers on the front lines Medical Liability Insurance • Business Analytics • Risk Management • Education COPYRIGHTED. Insurance products issued by ProSelect® Insurance Company and Preferred Professional Insurance Company® RHODE ISLAND M EDICAL J OURNAL 7 COMMENTARY Reflections on 2020, the year of COVID RIMJ EDITORS A Pandemic-Inspired Transformation of Primary Care JEFFREY BORKAN, MD, PhD PAUL GEORGE, MD, MHPE ELI Y.
    [Show full text]
  • Iron Is an Essential Nutrient 4 Bacteria and Humans
    Abstract The bhuTUV and bhuO genes play vital roles in the ability of Brucella abortus to use heme as an iron source and are regulated in an iron-responsive manner by RirA and Irr by Jenifer F. Ojeda April, 2012 Dissertation Advisor: RM Roop II Department of Microbiology and Immunology Brucella abortus is a Gram negative intracellular pathogen that causes the zoonotic disease brucellosis. Antibiotic treatment for brucellosis in humans is prolonged and sometimes followed by relapses. Currently, the United States employs prevention of the illness in humans through cattle vaccinations, eliminating the bacterium in its natural host. Unfortunately, these vaccine strains cause the disease in humans, and Brucella research ultimately aims to identify new vaccine targets as well as alternative treatment options. Brucella abortus resides in the phagosomal compartment of the host macrophage where essential nutrients such as iron are limited. Most bacteria need iron, and within the macrophage, heme is a likely source of iron due to the breakdown of red blood cells by the host macrophage. Heme transporters in Gram negative bacteria are highly conserved, and include components for outer membrane, periplasmic, and cytoplasmic membrane transport. BhuA has been previously characterized as the outer membrane heme transporter of Brucella abortus and here we report that BhuT, BhuU, and BhuV (BhuTUV) are the periplasmic and cytoplasmic heme transport components and that they are required in order for Brucella abortus to transport heme as an iron source. Utilization of heme as an iron source requires the breakdown of heme into ferrous iron, carbon monoxide, and biliverdin by a heme oxygenase.
    [Show full text]
  • Advertising & Marketing 2021
    Advertising & Marketing 2021 & Marketing Advertising Advertising & Marketing 2021 Contributing firm Frankfurt Kurnit Klein & Selz, PC © Law Business Research 2021 Publisher Tom Barnes [email protected] Subscriptions Claire Bagnall Advertising & [email protected] Senior business development manager Adam Sargent Marketing [email protected] Published by Law Business Research Ltd Meridian House, 34-35 Farringdon Street 2021 London, EC4A 4HL, UK The information provided in this publication Contributing firm is general and may not apply in a specific situation. Legal advice should always Frankfurt Kurnit Klein & Selz, PC be sought before taking any legal action based on the information provided. This information is not intended to create, nor does receipt of it constitute, a lawyer– client relationship. The publishers and authors accept no responsibility for any Lexology Getting The Deal Through is delighted to publish the eighth edition of Advertising & acts or omissions contained herein. The Marketing, which is available in print and online at www.lexology.com/gtdt. information provided was verified between Lexology Getting The Deal Through provides international expert analysis in key areas of February and March 2021. Be advised that law, practice and regulation for corporate counsel, cross-border legal practitioners, and company this is a developing area. directors and officers. Throughout this edition, and following the unique Lexology Getting The Deal Through format, © Law Business Research Ltd 2021 the same key questions are answered by leading practitioners in each of the jurisdictions featured. No photocopying without a CLA licence. Our coverage this year includes new chapters on Germany and Turkey. First published 2004 Lexology Getting The Deal Through titles are published annually in print.
    [Show full text]
  • The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine in This Issue
    June 2021 ISSN 1650-3414 Volume 32 Number 2 Communications and Publications Division (CPD) of the IFCC Editor-in-chief: Prof. János Kappelmayer, MD, PhD Faculty of Medicine, University of Debrecen, Hungary e-mail: [email protected] The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine In this issue Introducing the eJIFCC special issue on “POCT – making the point” Guest editor: Sergio Bernardini 116 Controlling reliability, interoperability and security of mobile health solutions Damien Gruson 118 Best laboratory practices regarding POCT in different settings (hospital and outside the hospital) Adil I. Khan 124 POCT accreditation ISO 15189 and ISO 22870: making the point Paloma Oliver, Pilar Fernandez-Calle, Antonio Buno 131 Utilizing point-of-care testing to optimize patient care James H. Nichols 140 POCT: an inherently ideal tool in pediatric laboratory medicine Siobhan Wilson, Mary Kathryn Bohn, Khosrow Adeli 145 Point of care testing of serum electrolytes and lactate in sick children Aashima Dabas, Shipra Agrawal, Vernika Tyagi, Shikha Sharma, Vandana Rastogi, Urmila Jhamb, Pradeep Kumar Dabla 158 Training and competency strategies for point-of-care testing Sedef Yenice 167 Leading POCT networks: operating POCT programs across multiple sites involving vast geographical areas and rural communities Edward W. Randell, Vinita Thakur 179 Connectivity strategies in managing a POCT service Rajiv Erasmus, Sumedha Sahni, Rania El-Sharkawy 190 POCT in developing countries Prasenjit Mitra, Praveen Sharma 195 In this issue How could POCT be a useful tool for migrant and refugee health? Sergio Bernardini, Massimo Pieri, Marco Ciotti 200 Direct to consumer laboratory testing (DTCT) – opportunities and concerns Matthias Orth 209 Clinical assessment of the DiaSorin LIAISON SARS-CoV-2 Ag chemiluminescence immunoassay Gian Luca Salvagno, Gianluca Gianfilippi, Giacomo Fiorio, Laura Pighi, Simone De Nitto, Brandon M.
    [Show full text]
  • Caries Vaccine: an Overview Dr
    Saudi Journal of Oral and Dental Research Abbreviated Key Title: Saudi J Oral Dent Res ISSN 2518-1300 (Print) |ISSN 2518-1297 (Online) Scholars Middle East Publishers, Dubai, United Arab Emirates Journal homepage: https://saudijournals.com/sjodr Review Article Caries Vaccine: An Overview Dr. Charvi Gupta*, Dr. Hemant Mankel Assistant Professor, Mekelle University, Ethiopia DOI: 10.36348/sjodr.2020.v05i05.003 | Received: 13.05.2020 | Accepted: 20.05.2020 | Published: 23.05.2020 *Corresponding author: Dr. Charvi Gupta Abstract One of the most common diseases in humans is dental caries. It is an infectious disease of microbiological origin that results in localized dissolution and destruction of the calcified tissue of teeth. It is a diseased caused by multitude of factors like host, agent and environmental factors. Microbes like S. mutans, Lactobacillus acidophilus and Actinomyces viscosus are the main pathogenic species involved with initiation and progression of dental caries. Indian surveys demonstrate caries prevalence of 58% in school children. Among the U.S. Population surveys showed 45.3% children and 93.8% of adults. A large costing of dental treatments whether prevention using remineralizing agents and treatment using restorative materials can be reduced if we could eradicate dental caries completely. Thus the ultimate objective of community health is the complete elimination of this disease. Development of dental caries vaccines is a boon for eradication of this microbiological disease. Keywords: Dental caries, infectious disease, microbes, S.mutans, prevention, dental caries vaccines. Copyright @ 2020: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.
    [Show full text]
  • Final Report of the Second Research Coordination Meeting
    IAEA-314-D4.10.24-CR/2 LIMITED DISTRIBUTION WORKING MATERIAL Use of Symbiotic Bacteria to Reduce Mass-Rearing Costs and Increase Mating Success in Selected Fruit Pests in Support of SIT Application Report of the Second Research Coordination Meeting of an FAO/IAEA Coordinated Research Project, held in Bangkok, Thailand, from 6 to 10 May 2014 Reproduced by the IAEA Vienna, Austria 2014 NOTE The material in this document has been supplied by the authors and has not been edited by the IAEA. The views expressed remain the responsibility of the named authors and do not necessarily reflect those of the government(s) of the designating Member State(s). In particular, neither the IAEA not any other organization or body sponsoring this meeting can be held responsible for any material reproduced in this document. 1 TABLE OF CONTENTS BACKGROUND ...................................................................................................................3 CO-ORDINATED RESEARCH PROJECT (CRP) ............................................................8 SECOND RESEARCH CO-ORDINATION MEETING (RCM) .......................................8 1 LARVAL DIETS AND RADIATION EFFECTS ..................................................... 10 BACKGROUND SITUATION ANALYSIS ................................................................................. 10 INDIVIDUAL PLANS ............................................................................................................ 13 1.1. Cost and quality of larval diet ...............................................................................
    [Show full text]
  • Plague (Yersinia Pestis)
    Division of Disease Control What Do I Need To Know? Plague (Yersinia pestis) What is plague? Plague is an infectious disease of animals and humans caused by the bacterium Yersinia pestis. Y. pestis is found in rodents and their fleas in many areas around the world. There are three types of plague: bubonic plague, septicemic plague and pneumonic plague. Who is at risk for plague? All ages may be at risk for plague. People usually get plague from being bitten by infected rodent fleas or by handling the tissue of infected animals. What are the symptoms of plague? Bubonic plague: Sudden onset of fever, headache, chills, and weakness and one or more swollen and painful lymph nodes (called buboes) typically at the site where the bacteria entered the body. This form usually results from the bite of an infected flea. Septicemic plague: Fever, chills, extreme weakness, abdominal pain, shock, and possibly bleeding into the skin and other organs. Skin and other tissues, especially on fingers, toes, and the nose, may turn black and die. This form usually results from the bites of infected fleas or from handling an infected animal. Pneumonic plague: Fever, headache, weakness, and a rapidly developing pneumonia with shortness of breath, chest pain, cough, and sometimes bloody or watery mucous. Pneumonic plague may develop from inhaling infectious droplets or may develop from untreated bubonic or septicemic plague after the bacteria spread to the lungs. How soon do symptoms appear? Symptoms of bubonic plague usually occur two to eight days after exposure, while symptoms for pneumonic plague can occur one to six days following exposure.
    [Show full text]
  • Annual Meeting
    Volume 97 | Number 5 Volume VOLUME 97 NOVEMBER 2017 NUMBER 5 SUPPLEMENT SIXTY-SIXTH ANNUAL MEETING November 5–9, 2017 The Baltimore Convention Center | Baltimore, Maryland USA The American Journal of Tropical Medicine and Hygiene The American Journal of Tropical astmh.org ajtmh.org #TropMed17 Supplement to The American Journal of Tropical Medicine and Hygiene ASTMH FP Cover 17.indd 1-3 10/11/17 1:48 PM Welcome to TropMed17, our yearly assembly for stimulating research, clinical advances, special lectures, guests and bonus events. Our keynote speaker this year is Dr. Paul Farmer, Co-founder and Chief Strategist of Partners In Health (PIH). In addition, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, will deliver a plenary session Thursday, November 9. Other highlighted speakers include Dr. Scott O’Neill, who will deliver the Fred L. Soper Lecture; Dr. Claudio F. Lanata, the Vincenzo Marcolongo Memorial Lecture; and Dr. Jane Cardosa, the Commemorative Fund Lecture. We are pleased to announce that this year’s offerings extend beyond communicating top-rated science to direct service to the global community and a number of novel events: • Get a Shot. Give a Shot.® Through Walgreens’ Get a Shot. Give a Shot.® campaign, you can not only receive your free flu shot, but also provide a lifesaving vaccine to a child in need via the UN Foundation’s Shot@Life campaign. • Under the Net. Walk in the shoes of a young girl living in a refugee camp through the virtual reality experience presented by UN Foundation’s Nothing But Nets campaign.
    [Show full text]